In recent days, shares of vaccine producer Novavax have experienced a steep decline of nearly 20% by market close. This drop came on the heels of remarks made by the U.S. Health and Human Services spokesperson Robert F. Kennedy Jr. during an interview with CBS News, where he raised concerns about the company’s COVID-19 vaccine. The news has stirred the financial markets, highlighting the critical balance between innovative breakthroughs and rigorous regulatory standards in the biotech industry.

Shares of Novavax Inc. have dropped significantly by 26% following recent statements made by U.S. Secretary of Health and Human Services Robert F. Kennedy Jr., who expressed doubts about the efficacy of the company’s COVID-19 vaccine. This development has caught the attention of both investors and health experts alike.

Blackstone Inc. $BX is actively negotiating the acquisition of VaxCare Corp. for approximately $1.7 billion, including debt. This news has significant implications not only for the investment community but also for stakeholders in the vaccine and healthcare markets.